Publicacións en colaboración con investigadores/as de Hospital do Meixoeiro (21)

2024

  1. Controversies in prostate cancer management: Consensus recommendations from experts in northern Spain

    Actas Urologicas Espanolas

  2. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer

    Clinical and Translational Oncology

2022

  1. Parkinson's disease and diabetes mellitus: Common mechanisms and treatment repurposing

    Neural Regeneration Research, Vol. 17, Núm. 8, pp. 1652-1658

2014

  1. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

    BMC Cancer, Vol. 14, Núm. 1

  2. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

    Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 160-166

  3. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: A multi-center phase II study

    Anticancer Research, Vol. 34, Núm. 4, pp. 1959-1966

2012

  1. COGENT (COlorectal cancer GENeTics) revisited

    Mutagenesis, Vol. 27, Núm. 2, pp. 143-151

2010

  1. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer

    British Journal of Cancer, Vol. 103, Núm. 10, pp. 1536-1541

  2. Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer

    Chemotherapy, Vol. 56, Núm. 2, pp. 142-146

  3. Colorectal cancer prognosis twenty years later

    World Journal of Gastroenterology, Vol. 16, Núm. 7, pp. 862-867

2009

  1. A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

    Cancer Chemotherapy and Pharmacology, Vol. 64, Núm. 2, pp. 379-384

2008

  1. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients

    Journal of Medical Genetics, Vol. 45, Núm. 9, pp. 557-563

2007

  1. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: A lung cancer Galician group phase II study

    Cancer Chemotherapy and Pharmacology, Vol. 60, Núm. 5, pp. 725-732

2006

  1. Neurotoxicidad secundaria a ifosfamida consecutivamente en forma de psicosis y coma

    Farmacia Hospitalaria

2004

  1. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study

    Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81

2003

  1. Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: A multicentre study of galician-lung-cancer-group

    Lung Cancer, Vol. 40, Núm. 2, pp. 215-220

  2. Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer

    Medical Oncology, Vol. 20, Núm. 1, pp. 37-43

2001

  1. Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma

    Cancer, Vol. 91, Núm. 4, pp. 704-711

1998

  1. Carcinoma microcitico extrapulmonar. Analisis de seis casos

    Oncologia, Vol. 21, Núm. 7, pp. 54-57

  2. Metastasis de leiomiosarcoma uterino en oido medio (hueso temporal). A proposito de un caso

    Oncologia, Vol. 21, Núm. 6, pp. 57-61